SCHEMBL2912880

SCHEMBL2912880

O=C(Nc1ccc(C2CCN(CC(O)CO)CC2)cc1C1=CCCCC1)C(F)(F)F

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIT P10721 9/20 0.52
CSF1R P07333 17/20 0.52
CYP3A4 P08684 6/20 0.51
CYP2C19 P33261 4/20 0.51
NTRK1 P04629 3/20 0.49
LCK P06239 3/20 0.49
AXL P30530 3/20 0.49
FLT3 P36888 3/20 0.49
CYP2C9 P11712 1/20 0.48
KCNH2 Q12809 1/20 0.47
BMPR1B O00238 1/20 0.45
PLK4 O00444 1/20 0.45
STK25 O00506 1/20 0.45
RIOK3 O14730 1/20 0.45
CHEK1 O14757 1/20 0.45
GAK O14976 1/20 0.45
DCLK1 O15075 1/20 0.45
MUSK O15146 1/20 0.45
EPHB6 O15197 1/20 0.45
PDPK1 O15530 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3086038 0.88 CSF1R (0.63) KITCSF1RCYP3A4CYP2C19NTRK1
SCHEMBL3093446 0.87 CSF1R (0.64) KITCSF1RCYP3A4CYP2C19NTRK1
SCHEMBL2913128 0.85 CSF1R (0.64) KITCSF1RCYP3A4CYP2C19NTRK1
SCHEMBL2913376 0.84 CSF1R (0.64) KITCSF1RCYP3A4CYP2C19NTRK1
SCHEMBL2914691 0.83 KIT (0.68) KITCSF1RCYP3A4CYP2C19NTRK1
SCHEMBL5260899 0.81 CSF1R (0.54) KITCSF1RCYP3A4CYP2C19NTRK1
SCHEMBL2909875 0.81 KIT (0.52) KITCSF1RCYP3A4CYP2C19NTRK1
SCHEMBL2913490 0.80 CSF1R (0.68) KITCSF1RCYP3A4CYP2C19NTRK1
SCHEMBL3173780 0.80 CSF1R (0.65) KITCSF1RCYP3A4CYP2C19NTRK1
SCHEMBL2913264 0.80 CSF1R (0.66) KITCSF1RCYP3A4CYP2C19NTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2222298-A1 USE OF CFMS INHIBITOR FOR TREATING OR PREVENTING BONE CANCER AND THE BONE LOSS AND BONE PAIN ASSOCIATED WITH BONE CANCER Janssen Pharmaceutica N.V. (BE) 2010-09-01 EP disclosed
WO-2009058801-A1 USE OF CFMS INHIBITOR FOR TREATING OR PREVENTING BONE CANCER AND THE BONE LOSS AND BONE PAIN ASSOCIATED WITH BONE CANCER JANSSEN PHARMACEUTICA, N.V. (BE) 2009-05-07 WO disclosed
EP-2015748-A2 METHOD OF INHIBITING C KIT KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2009-01-21 EP disclosed
EP-1951234-A2 METHOD OF INHIBITING FLT3 KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2008-08-06 EP disclosed
EP-1898912-A1 SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR JANSSEN PHARMACEUTICA N.V. (BE) 2008-03-19 EP disclosed
WO-2007124369-A2 METHOD OF INHIBITING C KIT KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-11-01 WO disclosed
EP-1807077-A2 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-18 EP disclosed
WO-2007048088-A2 METHOD OF INHIBITING FLT3 KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-04-26 WO disclosed
WO-2006138155-A1 SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR JANSSEN PHARMACEUTICA N.V. (BE) 2006-12-28 WO disclosed
WO-2006047277-A2 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-04 WO disclosed